A
Antonio Antela
Researcher at University of Santiago de Compostela
Publications - 15
Citations - 921
Antonio Antela is an academic researcher from University of Santiago de Compostela. The author has contributed to research in topics: Dolutegravir & Emtricitabine. The author has an hindex of 6, co-authored 15 publications receiving 733 citations.
Papers
More filters
Journal ArticleDOI
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Sharon Walmsley,Antonio Antela,Nathan Clumeck,Dan Duiculescu,Andrea Eberhard,Felix Gutieŕrez,Laurent Hocqueloux,Franco Maggiolo,Uriel Sandkovsky,Catherine Granier,Keith A. Pappa,Brian Wynne,Sherene Min,Garrett Nichols +13 more
TL;DR: Dolutegravir plus abacavir-lamivudine had a better safety profile and was more effective through 48 weeks than the regimen with efavirenz-tenofovir DF-emtricitabine, thus meeting the criterion for superiority.
Journal ArticleDOI
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial
Anton Pozniak,Martin Markowitz,Anthony Mills,Hans-Juergen Stellbrink,Antonio Antela,Pere Domingo,Pierre-Marie Girard,Keith Henry,Thai Nguyen,David Piontkowsky,Will Garner,Kirsten L. White,Bill Guyer +12 more
TL;DR: Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir seems to be efficacious and well tolerated in virologically suppressed adults with HIV and might be a suitable alternative for patients on an NNRTI with emTricitABine and ten ofovir regimen considering a regimen modification or simplification.
Journal ArticleDOI
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
Miranda Murray,Antonio Antela,Anthony Mills,Jenny Huang,Hans Jäger,Enrique Bernal,Johan Lombaard,Harold P. Katner,Sharon Walmsley,Marie-Aude Khuong-Josses,Krischan J Hudson,David Dorey,Sandy Griffith,William Spreen,Simon Vanveggel,Mark S. Shaefer,David A. Margolis,Vasiliki Chounta +17 more
TL;DR: The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral oral therapy, and further support the potential of a monthly injectable option for people living with HIV seeking an alternative to daily oral treatment.
Journal ArticleDOI
Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials.
Andrea Mantsios,Miranda Murray,Tahilin S. Karver,Wendy A. Davis,David Margolis,Princy Kumar,Susan Swindells,U. Fritz Bredeek,Miguel García del Toro,Mercedes Garcia Gasalla,Rafael Rubio García,Antonio Antela,Krischan J Hudson,Sandy Griffith,Deanna Kerrigan +14 more
TL;DR: The experiences of PLHIV participating in Phase 3 LA ART trials in the United States and Spain are sought, highlighting the importance of patient-provider communication related to weighing potential benefits and side effects and the continued need to address HIV stigma.
Journal ArticleDOI
Late presentation for HIV remains a major health issue in Spain: Results from a multicenter cohort study, 2004-2018
Marta Rava,Lourdes Domínguez-Domínguez,Otilia Bisbal,Luis F. López-Cortés,Carmen Busca,Antonio Antela,Patricia González-Ruano,Cristina Hernández,José-Antonio Iribarren,Rafael M. Rubio,Santiago Moreno,Inmaculada Jarrín +11 more
TL;DR: In this article, the authors used multivariable Poisson regression models to estimate both prevalence ratios (PR) for the association of potential risk factors with late presentation and incidence rate ratios (IRR) for its impact on the development of the composite endpoint (first ADE, first serious non-AIDS event [SNAE] or overall mortality).